Recent progress in design and preparation of glucose-responsive insulin delivery systems

Shen, Di; Yu, Haojie; Khan, Amin; Haq, Fazal; Chen, Xiang; Huang, Qiao; Teng, Lidong

doi:10.1016/j.jconrel.2020.02.014

Cited by 88 publications

(61 citation statements)

References 173 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 45 ] However, such intricate balance can become profoundly dysregulated in certain disorders such as Diabetes mellitus , which due to absence of insulin production or development of insulin resistance, are characterized by a significant increase (over 4‐fold) in circulating glucose concentration. [ 97–99 ] In the case of Type 1 diabetes, such patients are highly dependent on periodic administration of supraphysiological doses of insulin in order to reduce and maintain glucose blood levels. [ 97 ]…”

Section: Stimuli‐responsive Nanocomposite Hydrogels and Biomedical Apmentioning

confidence: 99%

Stimuli‐Responsive Nanocomposite Hydrogels for Biomedical Applications

Lavrador

Esteves

Gaspar

et al. 2020

Adv Funct Materials

342

201

View full text Add to dashboard Cite

The complex tissue‐specific physiology that is orchestrated from the nano‐ to the macroscale, in conjugation with the dynamic biophysical/biochemical stimuli underlying biological processes, has inspired the design of sophisticated hydrogels and nanoparticle systems exhibiting stimuli‐responsive features. Recently, hydrogels and nanoparticles have been combined in advanced nanocomposite hybrid platforms expanding their range of biomedical applications. The ease and flexibility of attaining modular nanocomposite hydrogel constructs by selecting different classes of nanomaterials/hydrogels, or tuning nanoparticle‐hydrogel physicochemical interactions widely expands the range of attainable properties to levels beyond those of traditional platforms. This review showcases the intrinsic ability of hybrid constructs to react to external or internal/physiological stimuli in the scope of developing sophisticated and intelligent systems with application‐oriented features. Moreover, nanoparticle‐hydrogel platforms are overviewed in the context of encoding stimuli‐responsive cascades that recapitulate signaling interplays present in native biosystems. Collectively, recent breakthroughs in the design of stimuli‐responsive nanocomposite hydrogels improve their potential for operating as advanced systems in different biomedical applications that benefit from tailored single or multi‐responsiveness.

show abstract

Section: Stimuli‐responsive Nanocomposite Hydrogels and Biomedical Apmentioning

confidence: 99%

Stimuli‐Responsive Nanocomposite Hydrogels for Biomedical Applications

Lavrador

Esteves

Gaspar

et al. 2020

Adv Funct Materials

342

201

View full text Add to dashboard Cite

show abstract

“…The three mechanisms relate to glucose interactions with glucose oxidase, phenylboronic acid and the lectin concanavalin A. These and others have recently been reviewed by Shen et al 59 Glucose oxidase (GOD) A common mechanism is the pH-linked change that is related to the coupled enzymatic oxidation of glucose to gluconic acid. 60 For GOD-related mechanisms, the insulin could be a passive passenger or may participate in the mechanism in some way, as exemplified by Fischel-Ghodsian and Newton many years ago in which the solubility of tri-lysyl insulin was manipulated by altering the net charge due to the GOD oxidation.…”

Section: Release Mechanism: 2 -Bolusmentioning

confidence: 99%

Gels for constant and smart delivery of insulin

2020

View full text Add to dashboard Cite

The focus of this review is the role of gelatinous materials for oral, transdermal and peritoneal insulin platforms as alternatives to the ubiquitous subcutaneous depot approach. Hydrogels that form hydrated, cohesive materials and the topologically complex micellar types can add ligand interaction, bond vulnerability and rheological characteristics to develop reliable programmed release, including closed loop (automated basal and bolus) activity in non-oral routes. In addition, the potential protection of the protein and likely increased paracellular uptake mean that orally active insulin is feasible. While unlikely to be suitable for closed loop delivery, the driver for gut absorption is not only to increase the convenience and decrease dosage trauma, but to target the mesentery-portal vasculature rather than peripheral tissue, thus improving hepatic glycogen equilibrium and reducing the obesogenic effect and hypoglycaemic episodes.

show abstract

“…Polymer-based technologies exploit sequestration of native or derivatised insulin within a matrix suitable for s.c. injection by directly integrating glucose-responsive components into delivery systems [73,74]. The matrix, in principle, senses the glucose concentration and releases a proportional amount of insulin.…”

Section: Polymer-based Gri Systemsmentioning

confidence: 99%

“…The set points of chemical equilibrium-based glucose-recognition technologies (relative to enzyme-or protein-based schemes) may be more amenable to optimisation than ConA systems were found to be. Polymer-based GRIs can, in principle, employ a variety of encapsulation chemistries, including polyethylene glycol (PEF), poly(N-vinyl-pyrrolidone) and succinyl-amidophenylglucopyranoside [31,74,85]. Whereas the matrices are impermeable to insulin during normoglycaemic or hypoglycaemic conditions, their permeability may increase as a result of physical changes that cause swelling or increased water solubility of the polymer in response to an increase in interstitial glucose concentration.…”

Section: Polymer-based Gri Systemsmentioning

confidence: 99%

‘Smart’ insulin-delivery technologies and intrinsic glucose-responsive insulin analogues

et al. 2021

View full text Add to dashboard Cite

Insulin replacement therapy for diabetes mellitus seeks to minimise excursions in blood glucose concentration above or below the therapeutic range (hyper-or hypoglycaemia). To mitigate acute and chronic risks of such excursions, glucose-responsive insulindelivery technologies have long been sought for clinical application in type 1 and long-standing type 2 diabetes mellitus. Such 'smart' systems or insulin analogues seek to provide hormonal activity proportional to blood glucose levels without external monitoring. This review highlights three broad strategies to co-optimise mean glycaemic control and time in range: (1) coupling of continuous glucose monitoring (CGM) to delivery devices (algorithm-based 'closed-loop' systems); (2) glucose-responsive polymer encapsulation of insulin; and (3) mechanism-based hormone modifications. Innovations span control algorithms for CGM-based insulin-delivery systems, glucose-responsive polymer matrices, bio-inspired design based on insulin's conformational switch mechanism upon insulin receptor engagement, and glucose-responsive modifications of new insulin analogues. In each case, innovations in insulin chemistry and formulation may enhance clinical outcomes. Prospects are discussed for intrinsic glucose-responsive insulin analogues containing a reversible switch (regulating bioavailability or conformation) that can be activated by glucose at high concentrations.

show abstract

Recent progress in design and preparation of glucose-responsive insulin delivery systems

Cited by 88 publications

References 173 publications

Stimuli‐Responsive Nanocomposite Hydrogels for Biomedical Applications

Stimuli‐Responsive Nanocomposite Hydrogels for Biomedical Applications

Gels for constant and smart delivery of insulin

‘Smart’ insulin-delivery technologies and intrinsic glucose-responsive insulin analogues

Contact Info

Product

Resources

About